— Know what they know.
Not Investment Advice

UPB NASDAQ

Upstream Bio, Inc.
1W: -3.8% 1M: -12.2% 3M: +4.7% YTD: -67.6% 1Y: +11.6%
$8.37
-0.09 (-1.06%)
 
Weekly Expected Move ±7.0%
$8 $8 $9 $10 $10
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 31 · $455.5M mcap · 20M float · 3.99% daily turnover · Short 30% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$455.5M
52W Range7.25-33.68
Volume255,445
Avg Volume800,598
Beta1.29
Dividend
Analyst Ratings
1 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOE. Rand Sutherland
Employees52
SectorHealthcare
IndustryBiotechnology
IPO Date2024-10-11
890 Winter Street
Waltham, MA 02451
US
781 208 2466
About Upstream Bio, Inc.

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Recent Insider Trades

NameTypeSharesPriceDate
GRAY MICHAEL S-Sale 852 $9.29 2026-03-16
Deykin Aaron S-Sale 894 $9.29 2026-03-16
Sutherland Everett R S-Sale 2,093 $9.29 2026-03-16
Ambrose Allison S-Sale 475 $9.29 2026-03-16
Houghton Adam S-Sale 699 $9.29 2026-03-16

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms